For myelodysplastic syndromes, current therapy is selected based on risk, transfusion needs, percent of bone marrow blasts, cytogenetic and mutational profiles, comorbidities, potential for allogeneic stem cell transplantation (alloSCT), and prior exposure to hypomethylating agents (HMA). Better diagnosis and prognostic stratification may allow a more precise and personalized treatment of MDS with novel agent combinations, […]
We use cookies to enhance your browsing experience; by continuing to use this site, you consent to the use of cookies in accordance with our privacy policy.AgreePrivacy policy